{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=47",
    "query": {
      "intervention": "Placebo,",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 33198,
    "total_pages": 3320,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T20:06:11.521Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03482167",
      "title": "NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Niagen®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Delaware",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "60 Years to 90 Years"
      },
      "enrollment_count": 64,
      "start_date": "2019-03-20",
      "completion_date": "2024-01-22",
      "has_results": true,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 1,
      "location_summary": "Newark, Delaware",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03482167"
    },
    {
      "nct_id": "NCT03088267",
      "title": "Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "amphetamine extended-release oral suspension, 2.5 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo extended-release oral suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 18,
      "start_date": "2017-02-11",
      "completion_date": "2017-10-30",
      "has_results": true,
      "last_update_posted_date": "2019-07-22",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03088267"
    },
    {
      "nct_id": "NCT03905811",
      "title": "A Pilot Study of Terazosin for Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Terazosin 5 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jordan Schultz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 13,
      "start_date": "2019-09-24",
      "completion_date": "2020-11-18",
      "has_results": true,
      "last_update_posted_date": "2022-05-16",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03905811"
    },
    {
      "nct_id": "NCT00002171",
      "title": "A Study of Viracept in HIV-Positive Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agouron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "13 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002171"
    },
    {
      "nct_id": "NCT01242371",
      "title": "Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Probiotic Supplement",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Identical-appearing Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Sheppard Pratt Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 65,
      "start_date": "2010-08",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2019-02-05",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 1,
      "location_summary": "Towson, Maryland",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01242371"
    },
    {
      "nct_id": "NCT04778644",
      "title": "Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "CBD"
      ],
      "interventions": [
        {
          "name": "CBD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hartford Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-12-15",
      "completion_date": "2025-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-04-12",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04778644"
    },
    {
      "nct_id": "NCT04241744",
      "title": "Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "CDI"
      ],
      "interventions": [
        {
          "name": "Vancomycin 125 MG po BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Creighton University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-10-29",
      "completion_date": "2020-01-13",
      "has_results": false,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04241744"
    },
    {
      "nct_id": "NCT04312009",
      "title": "Losartan for Patients With COVID-19 Requiring Hospitalization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Corona Virus Infection",
        "Acute Respiratory Distress Syndrome",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Losartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2020-04-13",
      "completion_date": "2021-02-01",
      "has_results": true,
      "last_update_posted_date": "2022-06-29",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 13,
      "location_summary": "Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Burnsville",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04312009"
    },
    {
      "nct_id": "NCT01632709",
      "title": "Pathophysiology of Post Amputation Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Amputation Stumps",
        "Neuroma"
      ],
      "interventions": [
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shirley Ryan AbilityLab",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2012-05",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2015-07-21",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01632709"
    },
    {
      "nct_id": "NCT00191009",
      "title": "Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "atomoxetine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2003-10",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2007-11-06",
      "last_synced_at": "2026-11-17T20:06:11.521Z",
      "location_count": 3,
      "location_summary": "Sherman Oaks, California • Rochester, New York • Wichita Falls, Texas",
      "locations": [
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Wichita Falls",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00191009"
    }
  ]
}